Beschreibung:
<jats:p><jats:bold>Study Objective.</jats:bold> To determine the safety of daptomycin administered using a variety of doses and dosing frequencies in patients receiving intermittent hemodialysis who had probable or confirmed gram‐positive infections.</jats:p><jats:p><jats:bold>Design.</jats:bold> Analysis of data from the Cubicin Outcomes Registry and Experience (CORE), a multicenter, retrospective, observational registry.</jats:p><jats:p><jats:bold>Setting.</jats:bold> Fifty‐four study sites, mostly (46%) large teaching hospitals.</jats:p><jats:p><jats:bold>Patients.</jats:bold> Three hundred ninety‐three adults in the CORE registry who received intermittent hemodialysis between 2005 and 2008.</jats:p><jats:p><jats:bold>Measurements and Main Results.</jats:bold> The CORE registry is noninterventional and collects standard‐of‐care data on daptomycin treatment from health care institutions. Of the 393 patients, 370 (94%) could be categorized by daptomycin dosing frequency: every 48 hours (251 patients [64%]), 3 times/week (87 [22%]), and every 24 hours (32 [8%]); the remaining 23 (6%) had unreported dosing frequencies or received a single dose of daptomycin. Three hundred eighty‐four patients (98%) received part of their daptomycin therapy as an inpatient and 129 patients (33%) received part of their daptomycin therapy in an intensive care setting. The primary infection type was bacteremia (224 patients [57%]), and the most common pathogen was <jats:italic>Staphylococcus aureus</jats:italic> (155 patients [39%]). Thirty‐eight adverse events possibly related to daptomycin occurred in 28 patients (7%); increased blood creatine kinase level (7 patients [1.8%]) was the most common adverse event. Adverse‐event rates were similar across all dosing regimens.</jats:p><jats:p><jats:bold>Conclusion.</jats:bold> In these patients undergoing hemodialysis, daptomycin was a well‐tolerated treatment for gram‐positive infections across several doses and dosing frequencies. Further study in prospective trials is warranted.</jats:p>